Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
1. A method of treatment of a human patient suffering from an ocular vascular disease selected from the group consisting of diabetic retinopathy, diabetic macular edema, retinal vein occlusion, central retinal vein occlusion, wet age-related macular degeneration, retinal neovascularization, choroidal neovascularization, and corneal neovascularization, the method comprising administering to the patient a bispecific antibody comprising a first antigen-binding site that specifically binds to human vascular endothelial growth factor (VEGF) and a second antigen-binding site that specifically binds to human angiopoietin-2 (ANG-2), wherein
i) said first antigen-binding site specifically binding to VEGF comprises in the heavy chain variable domain a CDR3H region of SEQ ID NO: 1, a CDR2H region of SEQ ID NO: 2, and a CDR1H region of SEQ ID NO:3, and in the light chain variable domain a CDR3L region of SEQ ID NO: 4, a CDR2L region of SEQ ID NO:5, and a CDR1L region of SEQ ID NO:6; and
ii) said second antigen-binding site specifically binding to ANG-2 comprises in the heavy chain variable domain a CDR3H region of SEQ ID NO: 9, a CDR2H region of, SEQ ID NO: 10, and a CDR1H region of SEQ ID NO: 11, and in the light chain variable domain a CDR3L region of SEQ ID NO: 12, a CDR2L region of SEQ ID NO: 13, and a CDR1L region of SEQ ID NO: 14, and wherein
iii) the bispecific antibody comprises a constant heavy chain region of human IgG1 or human IgG4 subclass (derived from human origin and) comprising the mutations I253A, H310A, and H435A (numbering according to EU Index of Kabat).
2. The method of claim 1 , wherein the antibody is administered via intravitreal application.
3. The method of claim 1 , wherein the ocular vascular disease is diabetic retinopathy.
4. The method of claim 1 , wherein the ocular vascular disease is diabetic macular edema.
5. The method of claim 1 , wherein the ocular vascular disease is retinal vein occlusion (RVO).
6. The method of claim 5 , wherein the retinal vein occlusion is central retinal vein occlusion (CRVO).
7. The method of claim 1 , wherein the ocular vascular disease is wet age-related macular degeneration (AMD).
8. The method of claim 1 , wherein the ocular vascular disease is choroidal neovascularization.
9. The method of claim 1 , wherein the antibody comprises a first heavy chain comprising the amino acid sequence of SEQ ID NO: 25, a first light chain comprising the amino acid sequence of SEQ ID NO: 27, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 26, and a second light chain comprising the amino acid sequence of SEQ ID NO: 28.
10. The method of claim 9 , wherein the antibody is administered via intravitreal application.
11. The method of claim 9 , wherein the ocular vascular disease is diabetic retinopathy.
12. The method of claim 9 , wherein the ocular vascular disease is diabetic macular edema.
13. The method of claim 9 , wherein the ocular vascular disease is retinal vein occlusion (RVO).
14. The method of claim 13 , wherein the retinal vein occlusion is central retinal vein occlusion (CRVO).
15. The method of claim 9 , wherein the ocular vascular disease is wet age-related macular degeneration (AMD).
16. The method of claim 9 , wherein the ocular vascular disease is choroidal neovascularization.